Agilon Health, Inc. (NYSE: AGL) announced a 1‑for‑25 reverse stock split that will become effective on March 30, 2026, at approximately 5:01 p.m. Eastern Time. Trading on a split‑adjusted basis will begin on March 31, 2026.
The split is intended to lift the company’s share price above the $1.00 minimum bid requirement set by the New York Stock Exchange. At the time of the announcement, the stock was trading at $0.59 and had reached a 52‑week low of $0.34 earlier in the year.
Agilon’s most recent quarterly results, released on March 18, 2026, showed an earnings‑per‑share loss of $0.46 versus the consensus estimate of a $0.27 loss, while revenue of $1.57 billion beat the forecast of $1.46 billion. For fiscal 2025, the company reported a gross loss of $160 million compared with a $5 million profit in 2024, and an Adjusted EBITDA loss of $296 million versus a $154 million loss in 2024. Management has stated that it expects to achieve breakeven Adjusted EBITDA in 2026.
Executive Chair Ronald A. Williams said, "While we were not satisfied by our 2025 financial performance, the transformation initiatives are delivering tangible benefits which support our expectation for material improvement in 2026. Based on the progress we have made and the momentum we are carrying into 2026, I am confident in our trajectory and firmly believe agilon and our partners are entering the next phase with a stronger foundation, a more resilient model, and a clear path to sustainable value creation." Chief Financial Officer Jeff Schwaneke added that the company’s cash position at the end of 2026 is $60 million better than anticipated, prompting a revision of the year‑end cash balance guidance to $125 million.
Analysts have responded with a neutral consensus, citing a median price target of $0.82, which represents a 38% upside from the current trading price of $0.59. The market reaction to the reverse split announcement was tempered by valuation concerns, but the revenue beat and the company’s stated turnaround plan provided a positive backdrop.
The reverse split signals Agilon’s ongoing turnaround strategy, which includes exiting unprofitable markets, tightening cost discipline, and focusing on operational efficiency. The company projects a positive medical margin of $300 million to $350 million for fiscal 2026, a significant swing from the negative $57 million margin reported in 2025. These developments suggest a shift toward a more sustainable, profitable model, though the company remains under pressure to meet NYSE compliance and to deliver on its financial targets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.